Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm

Group 1 - The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Tandem Diabetes Care, Inc. and may file a class action on behalf of investors [1] - Tandem's stock price fell by $2.87, or 19.9%, closing at $11.52 per share on August 7, 2025, due to the disclosure of a malfunction in its insulin pumps [2] - The malfunction could lead to a discontinuation of insulin delivery, potentially resulting in hyperglycemia and requiring hospitalization [2] Group 2 - Tandem had already distributed notices to affected customers regarding the malfunction between July 22 and 24, 2025, prior to the public market disclosure [2] - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [3]